Diamond Biofund
鑽石生技投資股份有限公司

2025 Q3 Earnings Conference Call

TWSE：6901

Disclaimer

- The forward-looking statements in this presentation, including operational outlooks, financial statements, and business forecasts, is based on internal data and the overall economic situation.
- Actual operational results, financial condition, and business outcomes in the future may differ from these predictive statements. This variance could be attributed to various factors, including but not limited to, operational and research risks associated with the Company's investment portfolios, changes in capital market trends, alterations in policies, laws, and financial economic conditions, as well as other uncontrollable risk factors.
- The Company's primary investment focus is in the biotechnology industry, where stock prices and fair values are significantly influenced by research outcomes, leading to substantial fluctuations. Consequently, a decrease in fair value may result in negative operating income.
- As a venture capital company primarily invested in the biotechnology industry, the nature of the Company's business involves lengthy development cycles, extensive capital investment, and no guaranteed success. Investors are advised to exercise special caution and diligence when considering investment.

Agenda

I. President's Remarks

II. Second Quarter 2025 Financial Results

III. Biotech Capital Dynamics and Portfolio

IV. Q&A

President's Remarks

Market vs. Biotech Index Performance Overview

Performance of the Capital Market and Biotech Index

	2025.9.24	YoY%
S&P 500	6,656.92	16.12%
TAIEX	26,196.73	16.78%
NASDAQ Biotech Index	4,805.87	0.88%
S&P 500 Health Care	1,597.63	-11.11%
TIP Taiwan BIO Index	4,159.69	-2.22%

Biopharma Venture Capital Funding Worldwide

	2025 Q2	2025 Q1
Amount	USD 4.5 billion	USD 6.7 billion

Source: JP Morgan

Relationship between Biotech VC Deployment and Interest Rates



Source: JP Morgan

- **The Chart demonstrate the relationships of 10Y US Treasury Yield vs. biotech VC deployment (2020–present)**
- **Negative correlation: Higher yields → Lower deployment**
- **Rate-cut stance (Trump Administration): VC activity likely to recover**

Biopharma Venture Capital Deployment Trends



- **In Q2 2025, biopharma venture capital funding totaled USD 4.5 billion**
- **Seed funding dropped by 80%, and Series A fell by 63%. Mid-to-late stage investment remained relatively stable, but with fewer deals and larger ticket sizes**

資料來源: DealForma.com

Changes in the Global Biotech Capital Market and Strategic Responses

Global Biotech Market

- Impact of U.S. Tariffs and Drug Pricing Reforms
- Global biotech capital market prices have rebounded, while biotech venture capital investment has remained stable. Interest rate cuts in the future are expected to stimulate venture capital activity
- Market focused on foreseeable revenue and clear exit potential, reducing the attractiveness of new platforms and early-stage assets

Responses

- Leverage cash reserves to maintain investment flexibility
- Prioritize flagship investment opportunities
- Support portfolio companies in fundraising, stretch capital efficiency, and build long-term value
- Monitor market and policy trends, and dynamically adjust investment strategies

2025 Asia-Pacific Biotech Investment Forum

Capital, policy, and global integration drive Taiwan's biotech forward

- Co-hosted by Diamond Biofund, TWSE, and TPEx
- 34 distinguished international speakers
- Over 500 leaders from industry, government, academia, and research attended

Biotech(48%)	76 biotech & pharma, 40 medtech, 35 healthcare services companies
Financial(26%)	75 venture capital, investment banking, life insurance, and asset management firms
Others(26%)	IBMI, DCB, Academia Sinica, ITRI, NTU, etc.

- Build an Asia-Pacific biotech investment platform
- Stay ahead of global biotech and capital market trends
- Enhance the impact of the biotech industry

2025 Asia-Pacific Biotech Investment Forum

TBF Biotech Lectures & Wu Ho-Su Medical Award Ceremony

Diamond Biofund's Commitment to Sustainable Biotech Talent

Support Outstanding Biotech & Pharma Scholars

17 Biotech Lectures
12 Wu Ho-Su Medical Awards

Promote Industry-Academia Collaboration

Over NT$400 Million in Total Funding

Commitment to Sustainable Talent Development

Trained over 100 postdocs, PhDs, and master's students

Agenda

I. President's Remarks

II. Second Quarter 2025 Financial Results

III. Biotech Capital Dynamics and Portfolio

IV. Q&A

Revenue Recognition

Revenue includes realized and unrealized valuation gains and losses of the portfolios. The valuation approach varies per the type of portfolio.

Portfolio Traded Actively in Capital Market(s)	Portfolio Not Traded Actively or Not in Capital Market(s)
Quoted price as of valuation day	Valuation per modeling – Market approach, Asset-based valuation approach or Option pricing model

Note 1 ：Closing price as of valuation day for TWSE/TPEx-listed shares
Note 2 ：Average trading price as of valuation day for TPEx Emerging Stock Board shares actively traded
Note 3 ：Valuation modeled for TPEx Emerging Stock Board shares not traded actively

2Q'25 Financial Results

Unit: NT$1,000

Item	2025 Q2	2024 Q2	2025 Q1-Q2
Revenue	(421,276)	(90,729)	(967,629)
Net Income (Loss)	(445,088)	(134,066)	(1,016,095)
Earnings (Loss) per Share	NT$(0.52)	NT$(0.16)	NT$(1.19)

Note：Revenue includes realized and unrealized gain and loss of financial assets

Unit: NT$1,000

Item	2025/06/30	2024/12/31
Cash and Cash Equivalent	3,030,709	126,228
Financial Assets at Fair Value through Profit or Loss	6,347,272	7,294,561
Net Assets	9,368,973	10,373,048
Total Assets	9,519,921	10,674,599

2Q'25 Financial Results

Total revenue amounted to negative NT 421,276 thousand for the three months ended June 30, 2025, with details as follows:

- **The negative revenue primarily arise from "unrealized" valuation losses of financial assets. Short-term price fluctuations do not affect the long-term investment value.**
- **Unrealized losses of financial assets primarily arise from:**
  - ✓ **Stock price changes from April 1, 2025 to June 30, 2025 of TPEx Emerging Stock Board portfolios**
  - ✓ **Unrealized losses from unlisted portfolios**

Agenda

I. President's Remarks

II. Second Quarter 2025 Financial Results

III. Biotech Capital Dynamics and Portfolio

IV. Q&A

International Biotech Capital Market

- Since the beginning of 2025, U.S. biotech stocks have experienced significant volatility and remain in a recovery phase, while the healthcare markets in Asia have demonstrated greater resilience.
- In the third quarter of this year, the international biotech capital market has focused on digital health and precision therapies, with investors showing a preference for companies that already have revenue-generating capabilities.



Source：NYSE, NASDAQ, Capital IQ

Major IPO in Q3: HeartFlow, Inc. (NASDAQ: HTFL)

IPO Case Summary	Digital Health
IPO Date	August 7, 2025
IPO Fundraising Amount	USD 364.2 Million
Market Cap (as of August 7, 2025)	USD 2.41 Billion

Major M&A in Q3: Verona Pharma plc (NASDAQ: VRNA)

M&A Case Summary	Biotech
Announcement Date	July 9, 2025
Acquirer	Merck
Target Company	Verona Pharma plc
Acquisition Amount	USD 10.97 Billion
Acquisition Premium	23%

Taiwan Biotech Capital Market

- As of the end of September 2025, a total of 8 new biotech companies have been listed Taiwan's stock markets (including emerging stocks). In 2024, a total of 19 new biotech companies were listed throughout the year.
- As of August 29, 2025, the overall market capitalization of the biotech industry in Taiwan was NT$1.92 trillion.

Market Segment	Total No. of Companies in 2024	Total No. of Companies in 3Q2025	Number of new listings	Total Market Cap as of 2025/08/29 (NT$ Billion)	Notes
TWSE	50	55	+ 5	989.4	ESB to TWSE*3 (Healthcare*1、Medical Devices*2) ESB to TWSE*1 (Shift from agri-tech to biotech) TPEx to TWSE*1
TPEx	92	94	+ 2	578.0	ESB to TPEx*3 (Medical Devices*2、New Drgus*1) TPEx to TWSE*1
Emerging Stock Board (ESB)	93	94	+ 1	355.2	Newly listed: New Drugs*6, Distribution*1, Medical Devices*1 Removed from ESB: ESB to TWSE*3, ESB to TPEx*3, delisted from ESB*1
Total	235	243	+ 8	1,922.7	

Source: Market Observation Post System (MOPs), Goodinfo (as of 2025/8/29)

Taiwan Biotech Capital Market

- As of the end of September 2025, biotech IPOs raised NT$12.9 billion, representing 26% of total IPO proceeds.
- Over the past two years, biotech has emerged as one of the most important growth sectors in Taiwan's IPO market.

Historical Biotech IPO Fundraising Amounts in Taiwan



2024 IPO Proceeds Breakdown (Total: NT$53.4 Billion)



2025 Q1-Q3 IPO Proceeds Breakdown (Total: NT$49.6 Billion, as of 2025/09)



Source: Market Observation Post System (MOPS), Goodinfo (as of 2025/9)

Investment Portfolio

New Drug Development & Cell/Gene Therapy

- StemCyte
- CHO Pharma
- Sinew Pharma
- ImmunAdd
- Rejuvenate
- Bilayer

Medical Devices & Others



- Theia Medical
- Tetanti AgriBiotech
- Syncell
- EyeYon
- KCP Fund I

New Drug Development and Cell/Gene Therapy

Company	Field	Core Project	Key Progress
StemCyte	Cell therapy	Umbilical cord blood for post-COVID treatment	World's first Phase II clinical trial met its endpoints; August 15: Phase III Clinical Trial Application Submitted to the US FDA
		Umbilical cord blood for acute stroke treatment	The IND for US Phase II clinical trial has been approved by the US FDA
		Autologous immune cell therapy for solid tumors	January 14: The MOHW (Taiwan) has approved a CIK cell therapy program by StemCyte and Taipei Medical University Hospital for treating solid tumors (Phase II–III) in patients unresponsive to standard treatments.
Cho Pharma	Glycoscience	Glycoengineered antibody with homogeneous glycan	The world's first glycoengineered antibody Phase I clinical trial has been completed and demonstrated safety. Preliminary results of Phase IIa trial have shown efficacy, with plans to conduct a Phase II expansion trial in 3Q25.
		Glycosite-specific ADC drugs	Seeking to enter into non-exclusive licensing agreements with international and domestic CDMO manufacturers to promote the CHOptimax™ technology platform for out-licensing of glycoengineered antibody drugs or ADC development.
		Bacterial vaccine	March 28: The bacterial vaccine (CHO-V08) was approved for Phase I clinical trial by the TFDA.
		Tumor antibody drug	August 9: Approved for Phase I clinical trial by the US FDA
Sinew Pharma	Liver disease	Non-hepatotoxic acetaminophen	April 10: The final report of the SNP-810 combination trial in knee replacement patients was announced, confirming liver safety and effective pain control.
		New drug for fatty liver disease	Phase I clinical trial has been completed, demonstrating safety. Phase II clinical trial enrollment will be initiated.
Rejuvenate Bio	Gene therapy	Desmoplakin arrhythmic cardiomyopathy	IND submission is in preparation.
		Mitral valve disease in dogs	Research agreement signed this year with a Top-5 global animal health company; upfront payment received.
ImmunAdd	Vaccine adjuvant	Synthetic saponin adjuvant	Applied MOEA A+ Program Grant for conducting IA-C01 GMP production and subsequent GLP toxicity studies.

Medical Devices & Others

Company	Field	Core Project	Key Progress
Syncell	Capture unknown proteins without labeling	Intracellular pickable microscope, consumables and analysis services	• Expanded global distribution partnerships and successfully installed equipment at Beijing National Protein Science Center. • Signed a strategic co-marketing agreement with Thermo Fisher Scientific to bring a fully integrated, high-resolution spatial proteomics workflow to the market.
EyeYon	Synthetic corneal endothelial layer	Artificial corneal implant	• EU: Commercially available, with EndoArt adopted by 64 hospitals across Europe. • China: Pivotal trial interim results show superior efficacy and 91% of patients achieved significant vision improvement. • USA: Received IDE approval and currently selecting clinical trial sites in US and other countries.
Theia	Medical semiconductor	Artificial retinal implant	• February 27: a domestic medical center successfully conducted a first-in-human artificial retinal implant surgery. • The first patient can distinguish two stripes with a 38 um gap (equivalent to 14 points). • Currently screening the second patient.
Tetanti AgriBiotech	Organic waste enzyme rapid processing technology	Organic waste treatment equipment and enzymes	A contract was signed with a domestic listed green energy company. A plant with a daily processing capacity of 100 tons of organic waste began commissioning in mid-September, expected to generate stable annual enzyme revenue of over NT$20 million.

Selected Investment Cases

ImmunAdd

- **Field** ：Vaccine Adjuvant
- **Jurisdiction** ：Taiwan
- **Structure**：Common Stock
- **Core Products**：Synthetic Saponin Adjuvant

Oversubscribed Capital Increase of NT$440 Million in Q3

- **ImmunAdd successfully completed fundraising this quarter, exceeding the original target of NT$300 million and raising NT$440 million in total. Diamond Biofund also increased its investment to support the company in completing its Phase 1 clinical trial.**
- **Use of funds**
  - ✓ Completion of the IA-C01 shingles vaccine Phase 1 clinical trial
  - ✓ International business development cooperation and licensing negotiations
- **Objectives**：Obtain human clinical data to drive international BD cooperation and subsequent licensing, supply-chain, or acquisition opportunities

Pipeline Progress and Clinical Roadmap

- I**AS-01(Adjuvant System)** : Benchmarked against GSK's AS-01 adjuvant system, composed of fully synthetic IA-05 (replacing QS-21) and IA-41 (glycolipid adjuvant); currently undergoing GMP manufacturing.
- In collaboration with the NHRI and mid-sized international pharmaceutical companies to develop influenza, cancer, and RSV vaccines.



Operational Progress

- Licensing Discussions : Multiple MTAs have been signed with major international pharmaceutical companies to initiate collaborative discussions. An international pharmaceutical company has also invited joint development of synthetic saponin adjuvants.
- Human clinical data will verify safety and vaccine efficacy, which are key factors for collaboration and licensing with international pharmaceutical companies. ImmunAdd will conduct the IA-C01 shingles vaccine clinical trial to provide safety and protective-effect evaluations.

Agenda

I. President's Remarks

II. Second Quarter 2025 Financial Results

III. Biotech Capital Dynamics and Portfolio

IV. Q&A

Invest in Biotech with
“Diamond Biofund“

Diamond Biofund helps you invest in elite biotech stocks!